Regulatory B BioPharm International
Alvotech Wins FDA Nod for 2nd Simlandi Manufacturing Suite
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
Regulatory headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Regulatory B BioPharm International
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
Regulatory A Applied Clinical Trials
A new request for information asks for comments on dose selection, safety monitoring, eligibility criteria, and oversight approaches to support the responsible development of ibogaine drug products.
Regulatory
STAT Biotech
Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Regulatory
FDA Press Announcements
The U.S. Food and Drug Administration today announced a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking public input on those approaches.
Regulatory
Clinical Trials Arena
The US FDA has cleared Surrozen’s investigational new drug (IND) application for SZN-8141 to begin clinical trial for diabetic macular oedema. The post Surrozen secures FDA clearance for SZN-8141 clinical trial appeared first on Clinical Trials Arena.
Regulatory
Pharmaceutical Technology
The US FDA has approved an expanded indication for Lilly's Jaypirca as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.
Regulatory
Bio.News
Continuing confusion about compliance is exacerbating the harms that new pharmaceutical tariffs cause the biotech industry, especially small innovative firms, experts say. Tariffs of […] The post Tariffs’ drag on innovation compounded by lack of guidance, experts say appeared fir…
Regulatory
Nature Reviews Drug Discovery
Regulatory
GEN
FDA Chief Scientist Steven Kozlowski, MD, said the updated FARS would come out early in FY 2027 but offered no further specifics on timing. The post FDA to Highlight Aging, Longevity Medicine in Planned FARS Update appeared first on GEN - Genetic Engineering and Biotechnology New…
Regulatory
MedCity News
Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical crea…
Regulatory
MedTech Dive
The device could help young patients avoid multiple open-heart surgeries as they grow, FDA officials said.
Regulatory
MedTech Dive
The FDA outlined its A-list and B-list guidance priorities for the 2027 fiscal year.
Regulatory F FDA Law Blog
By Steven J. Gonzalez & Peter G. Dickos & Adrienne R. Lenz, Principal Medical Device Regulation Expert —
Regulatory B BioPharm International
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Regulatory
FDA Press Announcements
The U.S. Food and Drug Administration today approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.
Regulatory B BioPharm International
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Regulatory P Pharmaceutical Executive
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
Regulatory
BioPharma Dive
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
Regulatory
MedTech Dive
The innovation challenge is focused on developing home devices that could help reduce hospital readmissions.
Regulatory
MedTech Dive
Medtronic plans to study the device in patients with peripheral artery disease below the knee, a historically difficult condition to treat.
Regulatory
MHRA
International statement co-developed by UK medicines regulator
Regulatory B BioPharm International
Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.
Regulatory P Pharmaceutical Executive
FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.
Regulatory
MedTech Dive
The regulatory authorizations come as Medtronic looks to differentiate itself in the fast-growing pulsed field ablation market targeted by rivals Abbott, Boston Scientific and J&J.
Regulatory
EMA Press
Marketing authorisation holders wishing to receive an outcome in 2026 should submit type IA annual updates, individual type IA and type IAIN variations, and super-groupings…
Regulatory
EMA Press
Mid-year report 2026 from the Executive DirectorEMA presented results and achievements of its operations for the first half of 2026 to the Management Board. Between January and…
Regulatory
BioPharma Dive
The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.
Regulatory
Clinical Trials Arena
If Trappsol Cyclo gets the regulatory greenlight, it could become the third drug to secure approval in Niemann Pick disease type C The post Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss appeared first on Clinical Trials Arena.
Regulatory
EMA Press
EMA has endorsed a joint statement from the International Coalition of Medicines Regulatory Authorities (ICMRA) calling on medicine developers, manufacturers, regulators and…
Regulatory
STAT Biotech
The small biotech company Invivyd is developing an injectable, low-dose monoclonal antibody to protect against Covid.
Regulatory
Pharmaceutical Technology
The US FDA has expanded the approved indication for BMS' Camzyos to treat symptomatic oHCM in adults and paediatric patients weighing at least 30 kg.
Regulatory P pharmaphorum
What's on the Agenda at the DIA-MHRA Global Summit Sara.Scarpinati Thu, 01/10/2026 - 09:00
Regulatory
EMA Press
Amsterdam, 28 September 2026Check against delivery (The published text is based on the prepared speech. Minor differences may have occurred during delivery)Good morning,…
Regulatory
MedCity News
The FDA is recruiting to fill vacancies on its advisory committees, informally known as adcomms. While these committees have met less frequently during the Trump administration, more meetings have been scheduled since former Commissioner Marty Makary left the agency in May. The p…
Regulatory B BioPharm International
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
Regulatory
BioPharma Dive
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.
Regulatory
MHRA
International leaders will gather to address some of the most significant opportunities and challenges facing healthcare today at the DIA-MHRA Global Summit.
Regulatory
BioPharma Dive
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
Regulatory
FDA Press Announcements
The U.S. Food and Drug Administration today announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees— the independent bodies that inform some of the most consequential decisions in American public health.
Regulatory
EMA Press
By the end of 2026, EMA will develop a regulatory roadmap to help drive decisive change on how women’s health is considered across medicines development and regulation. This…, Women are still missing: from research and data, prevention, diagnosis and treatment. But the momentum t…